Tebotelimab is under clinical development by MacroGenics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tebotelimab’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tebotelimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tebotelimab (MGD-013) is under development for the treatment of solid tumors including ovarian, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, triple negative breast cancer, gastric cancer, melanoma, intrahepatic cholangiocarcinoma or mixed hepatocellular metastatic biliary tract carcinoma-cholangiocarcinoma, gallbladder carcinoma and hematological malignancies. It is administered as intravenous infusion. The therapeutic candidate is a bi-specific, tetravalent antibody that acts by targeting PD1 and LAG-3. It is developed based on dual-affinity re-targeting (DART) technology platform.
It was also under development for the treatment of recurrent head and neck cancer squamous cell carcinoma.
MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, breast and gastroesophageal cancers, type 1 diabetes, HIV, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.
Quick View Tebotelimab LOA Data
|Highest Development Stage|